Neutrophils as emerging immunotherapeutic targets: Indirect treatment of tumors by regulating the tumor immune environment based on a sialic acid derivative-modified nanocomplex platform

Blockade of neutrophil recruitment to tumor sites based on sialic acid-modified nanoplatforms enhances the efficacy of checkpoint blockade immunotherapy

“…And the results showed that the preparation of SA-EPG-BCS had no hemolysis and condensation on rabbit red blood cells and could be used for injection (Table S2). And the other characteristics of drug release, stability, cell viability and neutrophil targeting ability of SA-EPG-BCS preparation were all consistent with the results of our previous studies [18] .…”

“…As described in previous work, SA-EPG-BCS is a phospholipid complex prepared from egg phosphatidylglycerol (EPG), a low-toxicity colchicine derivative BCS, and SA-CH, a modified ligand for the synthesis of sialic acid and cholesterol [18] . BCS, EPG, and SA-CH were dissolved in absolute ethanol, refluxed at 40 °C for 0.5 h, and ethanol was evaporated.…”

“…S1) as our model drug. We prepared a sialic acid (SA) - modified BCS phospholipid complex (the phospholipid is egg phosphatidylglycerol, EPG), and confirmed that this preparation (SA-EPG-BCS) could efficiently target peripheral blood neutrophils, inhibit their migration ability, and block the infiltration of tumor-associated neutrophils [18] .…”

Engineering and Targeting Neutrophils for Cancer Therapy

“…Hence, Chen et al have synthesized low-toxic colchicine derivative (BCS) nanocomposite and modified them with sialic acid and cholesterol derivatives (SA-CH) for improving neutrophil targeting. [145] They demonstrate that neutrophils effectively absorb SA-CH-modified BCS preparations, reduce infiltration of neutrophils into tumor, enhance T cell function, and effectively inhibit tumor growth and metastasis in a triple-negative breast cancer model. The value of nanomaterial-mediated delivery of specific antibodies or inhibitors for neutrophil expansion and recruitment in cancer therapy deserves further investigation in future studies.…”

A microfluidic model of human vascularized breast cancer metastasis to bone for the study of neutrophil-cancer cell interactions

“…Since the identification of TANs, the interplay between CCs and neutrophils was mainly investigated through the analysis of patient samples [ 16 ] and in vivo models [ 17 , 18 ]. These approaches led for instance to the development of innovative strategies to impair neutrophil migration and recruitment to the tumor microenvironment [ 19 ]. Recently, innovative in vitro 3D vascularized microphysiological systems were designed to analyze the role of neutrophils during CC extravasation and metastasis formation [ 20 , 21 ].…”